PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...

The trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach ...

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year ...

Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat ...

Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, into molecular subtypes using ...

Researchers at the University of Iowa found that adding high-dose IV vitamin C to chemotherapy helped increase survival in ...

The FDA advised that the on-going VIRAGE Phase 2b study should not be expanded into a Phase 3 study; rather, the optimal path forward for the VCN-01 PDAC program is to conduct a stand-alone Phase 3 ...

the sudden rise in pancreatic cancer incidence is largely being driven by another type of tumor — endocrine cancers. They tend to be indolent, taking years or even decades to grow and spread ...

The first type tends to take years to grow and spread, while the second is typically fast-moving and aggressive. "The increasing incidence of pancreatic cancer in younger Americans is primarily ...

Breast cancer, which was one of the most common cancers diagnosed at CoC sites, also had one of ... no uniform guidelines on ...

High doses of vitamin C, when combined with standard chemotherapy, may significantly extend the life expectancy of patients with advanced pancreatic cancer.